New eye drop offers hope for rare corneal disease

NCT ID NCT06452316

First seen Apr 13, 2026 · Last updated May 15, 2026 · Updated 2 times

Summary

This early-stage study tests an experimental eye drop called CSB-001 in 75 people with limbal stem cell deficiency, a condition that damages the cornea and can cause vision loss. Participants receive the drug in one or both eyes over two dosing periods separated by a break. The main goals are to check safety and see if the treatment improves signs of the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIMBAL STEM-CELL DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Francis Price Jr, MD

    RECRUITING

    Indianapolis, Indiana, 46260, United States

    Contact

  • Legacy Devers Eye Institute

    RECRUITING

    Portland, Oregon, 97210, United States

    Contact

  • Loma Linda University Eye Institute

    RECRUITING

    Loma Linda, California, 92354, United States

    Contact

  • Midwest Cornea Associates, LLC

    RECRUITING

    Carmel, Indiana, 46290, United States

    Contact

  • Minnesota Eye Consultants

    RECRUITING

    Minnetonka, Minnesota, 55305, United States

    Contact

  • Stuart A. Terry, MD PA

    RECRUITING

    San Antonio, Texas, 78212, United States

    Contact

Conditions

Explore the condition pages connected to this study.